帕博西利联合辅助内分泌治疗激素受体阳性浸润性乳腺癌的II期可行性研究
这项II期试验评估激素受体阳性/HER2阴性早期乳腺癌患者接受2年帕博西利(125 mg每日,服3周停1周)联合内分泌治疗的可行性,主要终点为因毒性、不依从或耐受性相关事件停药。162例中102例(63%)完成2年治疗,方案相关提前停药率31%(95%CI 24%–39%,P=0.001),12个月累积停药发生率21%(95%CI 14%–27%),未发生发热性中性粒细胞减少,56%需至少一次剂量下调。作者结论认为辅助帕博西利可行且多数患者可耐受。
要点
- 162例激素受体阳性/HER2阴性II–III期乳腺癌患者启动帕博西利,102例(63%)完成2年治疗。
- 方案相关提前停药31%(95%CI 24%–39%,P=0.001),12个月累积停药发生率21%(95%CI 14%–27%)。
- 帕博西利相关毒性发生率与转移性乳腺癌经验一致,无发热性中性粒细胞减少病例,56%需至少一次剂量下调。
核心结论
- 辅助帕博西利在早期乳腺癌中可行,高比例患者能完成2年治疗。
- 辅助治疗的安全性与转移性疾病中观察到的相似,约半数患者需要剂量调整。
- 作者认为延长疗程的辅助帕博西利对多数患者似乎可行且可耐受,随机III期试验正在评估该人群的临床获益。
研究设计与样本
- II期可行性试验,纳入激素受体阳性/HER2阴性II–III期乳腺癌患者。
- 患者接受2年帕博西利125 mg每日,服3周停1周,联合内分泌治疗。
- 主要终点为因毒性、不依从或耐受性相关事件停用帕博西利。
- 停药率48%或更高提示2年治疗时长不可行,采用单侧α=0.025的二项检验评估。
- 共162例患者启动帕博西利,超过半数(52%)为III期,多数(80%)接受过化疗。
主要发现
- 102例(63%)完成2年帕博西利治疗;50例因方案相关原因提前停药(31%,95%CI 24%–39%,P=0.001),10例因方案无关原因停药。
- 自治疗开始12个月时方案相关停药的累积发生率为21%(95%CI 14%–27%)。
- 帕博西利相关毒性发生率与转移性乳腺癌经验一致,无发热性中性粒细胞减少病例。
- 91例(56%)需要至少一次剂量下调。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The CDK4/6 inhibitor palbociclib prolongs progression-free survival in hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer when combined with endocrine therapy. This phase II trial was designed to determine the feasibility of adjuvant palbociclib and endocrine therapy for early breast cancer. PATIENTS AND METHODS: Eligible patients with HR+/HER2- stage II-III breast cancer received 2 years of palbociclib at 125 mg daily, 3 weeks on/1 week off, with endocrine therapy. The primary end point was discontinuation from palbociclib due to toxicity, non-adherence, or events related to tolerability. A discontinuation rate of 48% or higher would indicate the treatment duration of 2 years was not feasible, and was evaluated under a binomial test using a one-sided α = 0.025. RESULTS: Overall, 162 patients initiated palbociclib; over half had stage III disease (52%) and most received prior chemotherapy (80%). A total of 102 patients (63%) completed 2 years of palbociclib; 50 patients discontinued early for protocol-related reasons (31%, 95% CI 24% to 39%, P = 0.001), and 10 discontinued due to protocol-unrelated reasons. The cumulative incidence of protocol-related discontinuation was 21% (95% CI 14% to 27%) at 12 months from start of treatment. Rates of palbociclib-related toxicity were congruent with the metastatic experience, and there were no cases of febrile neutropenia. Ninety-one patients (56%) required at least one dose reduction. CONCLUSION: Adjuvant palbociclib is feasible in early breast cancer, with a high proportion of patients able to complete 2 years of therapy. The safety profile in the adjuvant setting mirrors that observed in metastatic disease, with approximately half of the patients requiring dose-modification. As extended duration adjuvant palbociclib appears feasible and tolerable for most patients, randomized phase III trials are evaluating clinical benefit in this population. CLINICALTRIALS.GOV REGISTRATION: NCT02040857.
引用
- Mayer EL, DeMichele A, Rugo HS, et al. A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019. PMID: 31250880. doi:10.1093/annonc/mdz198
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。